Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis

The American Journal of Psychiatry
Thomas H McGlashanAlan Breier

Abstract

This study assessed the efficacy of olanzapine in delaying or preventing conversion to psychosis and reducing symptoms in people with prodromal symptoms of schizophrenia. This randomized trial occurred at four North American clinics in the Prevention Through Risk Identification, Management, and Education project. Outpatients received olanzapine (5-15 mg/day, N=31) or placebo (N=29) during a 1-year double-blind treatment period and no treatment during a 1-year follow-up period. Efficacy measures included the conversion-to-psychosis rate and Scale of Prodromal Symptoms scores. During the treatment year, 16.1% of olanzapine patients and 37.9% of placebo patients experienced a conversion to psychosis, a nearly significant difference. The hazard of conversion among placebo patients was about 2.5 times that among olanzapine-treated patients, which also approached significance. In the follow-up year, the conversion rate did not differ significantly between groups. During treatment, the mean score for prodromal positive symptoms improved more in the olanzapine group than in the placebo group, and the mixed-model repeated-measures least-squares mean score showed significantly greater improvement between weeks 8 and 28 with olanzapine. T...Continue Reading

Citations

Jan 9, 2008·Archives of General Psychiatry·Tyrone D CannonRobert Heinssen
Dec 17, 2008·Neurotoxicity Research·Tomas PalomoTrevor Archer
Aug 24, 2011·Social Psychiatry and Psychiatric Epidemiology·Yu-Chen KaoYia-Ping Liu
May 29, 2012·Applied Microbiology and Biotechnology·Zhixiong XueQuinn Zhu
Jul 3, 2008·European Archives of Psychiatry and Clinical Neuroscience·Joachim KlosterkötterStephan Ruhrmann
Oct 16, 2010·European Archives of Psychiatry and Clinical Neuroscience·Stephan RuhrmannJoachim Klosterkötter
Sep 21, 2007·Current Psychiatry Reports·Matcheri S Keshavan, Ali Amirsadri
Sep 8, 2010·Current Psychiatry Reports·Elizabeth HansonChristian Kohler
Feb 22, 2012·Current Psychiatry Reports·Sibel AlgonKarin E Borgmann-Winter
Feb 26, 2013·CNS Drugs·Chen-Chung Liu, Arsime Demjaha
Oct 24, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Scott W WoodsJohn H Krystal
Apr 10, 2009·Psychological Medicine·L R ValmaggiaP K McGuire
Jul 9, 2008·Development and Psychopathology·David J Miklowitz, Kiki D Chang
Jun 22, 2012·Behavioural and Cognitive Psychotherapy·Hannah E TaylorAnthony P Morrison
Oct 26, 2011·Molecular Psychiatry·J YangC Wan
Jun 29, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Masakuni HoriguchiHerbert Y Meltzer
Jul 16, 2008·The Australian and New Zealand Journal of Psychiatry·GeumSook ShimJun Soo Kwon
Jan 21, 2009·The Australian and New Zealand Journal of Psychiatry·Alison R YungElizabeth M Cosgrave
Aug 12, 2009·The Australian and New Zealand Journal of Psychiatry·Lisa J PhillipsPatrick D McGorry
Mar 11, 2011·Cognitive Neuropsychiatry·Anthony S David
Apr 15, 2009·Journal of Child and Adolescent Psychopharmacology·Chadi A CalargeJanet A Schlechte
Mar 1, 2012·Journal of Child and Adolescent Psychopharmacology·Ludmila A KryzhanovskayaOlawale Osuntokun
Oct 10, 2008·Cerebral Cortex·Paul M ThompsonUNKNOWN HGDH Study Group
May 8, 2007·Schizophrenia Bulletin·Thomas H McGlashanAlison Yung
May 2, 2007·Schizophrenia Bulletin·Tyrone D CannonPatrick McGorry
Jul 17, 2007·Schizophrenia Bulletin·Ralph E Hoffman
Jun 27, 2008·Schizophrenia Bulletin·Frauke Schultze-LutterJoachim Klosterkötter
Feb 7, 2007·Current Opinion in Psychiatry·Eóin Killackey, Alison R Yung
Jun 7, 2007·Current Opinion in Psychiatry·George C PattonPatrick McGorry
Jun 26, 2009·Current Opinion in Psychiatry·Stephan RuhrmannJoachim Klosterkötter
Dec 3, 2010·Current Opinion in Psychiatry·Barnaby Nelson, Alison R Yung
May 26, 2012·Psychiatry and Clinical Neurosciences·Rodrigo Barbachan MansurElisa Brietzke
Jul 29, 2006·BMJ : British Medical Journal·David Kingdon
Jan 22, 2013·BMJ : British Medical Journal·Megan R StaffordTim Kendall
Mar 29, 2008·Annual Review of Clinical Psychology·Elaine WalkerKevin Tessner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here